Epidemiological Studies on Type 2 Diabetes Using the German Disease Analyser Database: A Narrative Review

作者：Kostev K, Sievert H, Konrad M, Sarabhai T · 发表于：Diabetes, obesity & metabolism · 年份：2026 · DOI：10.1111/dom.71089 · 研究领域：GLP‐1 receptor agonists、Germany、SGLT2 inhibitors、disease analyser、pharmacoepidemiology、real‐world evidence、type 2 diabetes

BACKGROUND: The German IQVIA Disease Analyser (DA) database provides longitudinal, anonymised outpatient data from a large network of German general practices and specialist offices, including ICD-10 diagnoses, ATC-coded prescriptions, consultation dates and selected clinical measurements (HbA1c, BMI). AIMS: This narrative review synthesises DA-based research in patients with type 2 diabetes (T2D) published between 2020 and 2025, with a focus on studies examining glucose-lowering drug effectiveness, real-world prescribing patterns, pharmacoepidemiological associations and relevant comorbidities. METHODS: A structured PubMed search was used to identify eligible studies, and methodological limitations of the included observational studies are discussed. RESULTS: Key findings include observational associations between SGLT2 inhibitor therapy and lower incidence of iron deficiency anaemia and dementia in patients with T2D, a decline in cardiovascular event incidence among patients with newly diagnosed T2D over a 17-years period, a gap between guideline recommendations and real-world use of GLP-1 receptor agonists and SGLT2 inhibitors in patients with established cardiovascular disease, and associations between glucose-lowering drug classes and cerebrovascular outcomes. DISCUSSION: Given the observational design of all included studies, these associations should be regarded as hypothesis-generating rather than causal. The DA database complements randomised trial evidence by ca...